{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:58:24Z","timestamp":1779904704017,"version":"3.53.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"16","funder":[{"DOI":"10.13039\/100004334","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.2217\/imt-2023-0073","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:46:02Z","timestamp":1694425562000},"page":"1375-1387","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Utilization of Immune Checkpoint Inhibitors in Extensive Stage Small-Cell Lung Cancer in Community Settings"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8399-7779","authenticated-orcid":false,"given":"Ke","family":"Zu","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ\ufffd\ufffd07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Arunachalam","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ\ufffd\ufffd07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriana","family":"Hohlbauch","sequence":"additional","affiliation":[{"name":"Ontada, The Woodlands, TX\ufffd\ufffd77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-7048","authenticated-orcid":false,"given":"Michelle","family":"Silver","sequence":"additional","affiliation":[{"name":"Ontada, The Woodlands, TX\ufffd\ufffd77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Robert","sequence":"additional","affiliation":[{"name":"Ontada, The Woodlands, TX\ufffd\ufffd77380, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_6_4_1","volume-title":"StatPearls.","author":"Basumallik N","year":"2021","unstructured":"Basumallik N , AgarwalM. Small cell lung cancer. StatPearls.Treasure Island, FL, USA (2021)."},{"key":"e_1_3_6_5_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program . Small cell carcinoma of the Lung and Bronchus. Recent trends in SEER Age-Adjusted Incidence Rates 2015\u20132019. (2019). https:\/\/seer.cancer.gov\/explorer\/application.html?site=611&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4481"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds213"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6601"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040270"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.37699"},{"key":"e_1_3_6_13_1","unstructured":"US Food and Drug Administration . FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. (August 20 2018). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-nivolumab-accelerated-approval-third-line-treatment-metastatic-small-cell-lung-cancer"},{"key":"e_1_3_6_14_1","unstructured":"US Food and Drug Administration . FDA approves pembrolizumab for metastatic small cell lung cancer. (June 18 2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer"},{"key":"e_1_3_6_15_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology . Small Cell Lung Cancer Version 2.2023. (October 28 2022). www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf"},{"key":"e_1_3_6_16_1","unstructured":"US Food and Drug Administration . FDA approves atezolizumab for extensive-stage small cell lung cancer. (March 19 2019). www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer"},{"key":"e_1_3_6_17_1","unstructured":"US Food and Drug Administration . FDA approves durvalumab for extensive-stage small cell lung cancer. (March 30 2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00979-1"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103335"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.29_suppl.288"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8561"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.661"},{"key":"e_1_3_6_23_1","unstructured":"The US Oncology Network (2022). www.usoncology.com\/our-company"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03414-4"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00207-6"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01221-4"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100712"},{"key":"e_1_3_6_28_1","unstructured":"Merck Provides Update on KEYTRUDA\u00ae (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US. www.merck.com\/news\/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us\/"},{"key":"e_1_3_6_29_1","unstructured":"Bristol Myers Squibb Statement on Opdivo (nivolumab) Small Cell Lung Cancer U.S. Indication. (December 29 2020). https:\/\/news.bms.com\/news\/details\/2020\/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Small-Cell-Lung-Cancer-US-Indication\/default.aspx"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.008"},{"issue":"50","key":"e_1_3_6_31_1","article-title":"Current updates in management of relapsed\/refractory small cell lung cancer","volume":"6","author":"Abughanimeh O","year":"2020","unstructured":"Abughanimeh O , ErnaniV , MarrA , GantiAK. Current updates in management of relapsed\/refractory small cell lung cancer. J. Cancer Metastasis Treat.6(50), (2020).","journal-title":"J. Cancer Metastasis Treat."},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00204"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.06.002"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272302"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4905"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.071"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0951"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:23:09Z","timestamp":1718198589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.2217\/imt-2023-0073"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0073","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}